CVE-2026-5209 SourceCodester CVE debrief

Who should care

Users of SourceCodester Leave Application System 1.0 should be aware of this cross-site scripting vulnerability and take steps to mitigate it. This includes applying patches or updates provided by the vendor, if available, and implementing input validation and output encoding to prevent cross-site scripting attacks.

Technical summary

The vulnerability is located in the User Management Handler component of SourceCodester Leave Application System 1.0. An attacker can inject malicious scripts into the application, potentially leading to unauthorized actions or data breaches. The vulnerability has a CVSS score of 1.9, indicating a low severity. This issue requires specific conditions to be exploited. Users should verify affected product deployments and review official advisories for validation. Evidence is limited, and defenders should implement input validation and output encoding to prevent cross-site scripting attacks. No additional technical details are available beyond public disclosure.

Defensive priority

Low priority, as the vulnerability has a low CVSS score and may require specific conditions to be exploited.

Recommended defensive actions

• Apply patches or updates provided by the vendor, if available.
• Implement input validation and output encoding to prevent cross-site scripting attacks.
• Monitor the application for suspicious activity and implement logging and incident response measures.
• Review compensating controls for exposed systems while remediation is scheduled and verified.
• Check relevant monitoring, detection, and logs for exposed assets that need extra review.
• Track exceptions, retest remediated assets, and close the item only after evidence is documented.
• Confirm whether affected product deployments exist in managed environments and assign an owner for follow-up.

Evidence notes

The vulnerability has been disclosed publicly and may be used by attackers. The exploit has been disclosed publicly. Evidence is limited, and defenders should verify affected product deployments and review official advisories for validation. No additional technical details are available.

Official resources